Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Account Payables (2021 - 2025)

Historic Change in Account Payables for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to -$4.0 million.

  • Krystal Biotech's Change in Account Payables fell 451758.24% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $418000.0, marking a year-over-year decrease of 6971.01%. This contributed to the annual value of $1.0 million for FY2024, which is 110099.01% up from last year.
  • Per Krystal Biotech's latest filing, its Change in Account Payables stood at -$4.0 million for Q3 2025, which was down 451758.24% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Change in Account Payables registered a high of $4.1 million during Q2 2025, and its lowest value of -$4.0 million during Q3 2025.
  • Its 5-year average for Change in Account Payables is $72473.7, with a median of $107000.0 in 2023.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 57943.93% in 2024, then plummeted by 451758.24% in 2025.
  • Krystal Biotech's Change in Account Payables (Quarter) stood at $937000.0 in 2021, then crashed by 200.11% to -$938000.0 in 2022, then soared by 76.33% to -$222000.0 in 2023, then plummeted by 166.22% to -$591000.0 in 2024, then plummeted by 580.2% to -$4.0 million in 2025.
  • Its Change in Account Payables stands at -$4.0 million for Q3 2025, versus $4.1 million for Q2 2025 and $906000.0 for Q1 2025.